ChEMBL logo

ChEMBL

spacer
ChEMBL Statistics
  Loading Statistics...
spacer

Compound Report Card

Compound Name and Classification

Compound ID CHEMBL2108611
CHEMBL2108611
Compound Name INOTUZUMAB OZOGAMICIN
ChEMBL Synonyms INOTUZUMAB OZOGAMICIN | CMC-544 | PF-05208773 | Besponsa | WAY-207294 | WAY-207294 CMC-544
Max Phase 4 (Approved)
Trade Names Besponsa

Sources

  • Clinical Candidates
  • Manually Added Drugs
  • USP Dictionary of USAN and International Drug Names
  • WHO Anatomical Therapeutic Chemical Classification

Molecule Features

CHEMBL2108611 compound icon
Drug Type:Antibody Rule of Five:N First In Class:Y Chirality:Single Stereoisomer Prodrug:N Oral:N Parenteral:Y Topical:N Black Box:Y Availability Type:Prescription-only

Mechanism of Action

Mechanism of Action ChEMBL Target References
CD22 binding agent CD22 PubMed

Indications

MESH Heading MESH ID EFO ID EFO Term Max phase for indication References
Lymphoma, FollicularD008224EFO:0000096neoplasm of mature B-cells3ClinicalTrials
Precursor B-Cell Lymphoblastic Leukemia-LymphomaD015452EFO:0000094B-cell acute lymphoblastic leukemia4FDA
NeoplasmsD009369EFO:0000616neoplasm4ATC
LeukemiaD007938EFO:0000565leukemia1ClinicalTrials
Lymphoma, Large B-Cell, DiffuseD016403EFO:0000403diffuse large B-cell lymphoma2ClinicalTrials
LymphomaD008223EFO:0000574lymphoma2ClinicalTrials
Lymphoma, Non-HodgkinD008228EFO:0005952non-Hodgkins lymphoma3ClinicalTrials
Precursor Cell Lymphoblastic Leukemia-LymphomaD054198EFO:0000220acute lymphoblastic leukemia3ClinicalTrials

Clinical Data

ClinicalTrials.gov INOTUZUMAB OZOGAMICIN
The Cochrane Collaboration INOTUZUMAB OZOGAMICIN

Compound Cross References

ATC L - ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 - ANTINEOPLASTIC AGENTS
L01X - OTHER ANTINEOPLASTIC AGENTS
L01XC - Monoclonal antibodies
L01XC26 - inotuzumab ozogamicin

ChemSpider ChemSpider Identifier not yet assigned
DailyMed inotuzumab ozogamicin
spacer
spacer